<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00660452</url>
  </required_header>
  <id_info>
    <org_study_id>VO55.06 CHIN</org_study_id>
    <nct_id>NCT00660452</nct_id>
  </id_info>
  <brief_title>A Phase III Study to Assess Efficacy and Safety of STALORAL® 300 IR Sublingual Immunotherapy (SLIT) in Asthmatic Patients Allergic to House-dust Mites</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Multi-centre, Phase III Study to Assess Efficacy and Safety of STALORAL® 300 IR Sublingual Immunotherapy (SLIT) in Chinese Asthmatic Patients Allergic to House-dust Mites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stallergenes Greer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stallergenes Greer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase III study to assess the efficacy and safety of sublingual immunotherapy with STALORAL
      dust mites solution compared with placebo for reduction of asthma symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>determine the proportion of patients who achieve well-controlled asthma with SLIT compared to placebo</measure>
    <time_frame>September 2009</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Daily dose of steroids at the endpoint Number of asthma exacerbations Asthma Control Questionnaire(ACQ)score Asthma Quality of Life Questionnaire (AQLQ) score Lung Function Parameters ( FEV1; FEF 25-75 %; PEF) Allergic rhinitis g</measure>
    <time_frame>September 2009</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">484</enrollment>
  <condition>Allergy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>360 active patients with house dust mites related asthma with or without allergic rhinitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>180 patients in the placebo group with house -dust mites related asthma with or without allergic rhinitis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Staloral</intervention_name>
    <description>Sublingual immunotherapy with Staloral dust mites solution</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female outpatients aged 16 to 50 years (inclusive).

          2. House dust mite-induced allergic asthma with or without perennial allergic rhinitis
             for at least 1 year.

          3. Sensitised to D. pteronyssinus and D.farinae (positive skin prick test (SPT) with
             wheal diameter ≥ 4 mm and specific IgE level ≥ 0.70 kU/L

          4. Patients treated with inhaled corticosteroids (ICS) before the screening visit at a
             dose ≥ 200 µg and &lt; 1,000 µg equivalent budesonide/day.

        Exclusion Criteria:

          1. Mild intermittent asthma needed to be treated only with β2-agonist (GINA level 1).

          2. Severe asthma needed to be treated with inhaled corticosteroids with a dose ≥ 1,000
             µg/day equivalent budesonide.

          3. FEV1 &lt; 70% of predicted value at Visit 1.

          4. Co-sensitisation to other inhalant allergens than dust mites leading to clinically
             relevant allergic asthma and proven by a positive skin prick test with wheal diameter
             ≥ 4 mm and serum specific IgE ≥ 0.70 KU/L .

          5. Patients with a past or current disease, which as judged by the investigator, may
             affect the patient's participation in or the outcome of the study. These diseases
             include, but are not limited to, past or current cardiovascular disease, malignancy,
             hepatic disease, renal disease, haematological disease, neurological disease,
             immunological disease and endocrine disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jia YIN, Pr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital -</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2008</study_first_submitted>
  <study_first_submitted_qc>April 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2008</study_first_posted>
  <last_update_submitted>October 10, 2011</last_update_submitted>
  <last_update_submitted_qc>October 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allergy</keyword>
  <keyword>SLIT</keyword>
  <keyword>Asthma</keyword>
  <keyword>House Dust Mites</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

